Printer Friendly Version 

2014 Press Releases

Keyword Search
 
2014 | 2013 | 2012 | 2011
DateTitle 
12/16/14Isis Pharmaceuticals Initiates Phase 1/2 Study of ISIS-DMPK Rx in Patients With Myotonic Dystrophy Type 1
ISIS-DMPK Rx Extends the Targeting of Antisense Drugs to Include Muscle Tissue CARLSBAD, Calif., Dec. 16, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated a study for ISIS-DMPKRx in patients with Myotonic Dystrophy Type 1 (DM1).  DM1 is a rare genetic neuromuscular disease caused by the production of toxic dystrophia myotonica-protein kinase (DMPK) RNA in cells.  ISIS-DMPKRx is specifically designed to reduce toxic DMPK RNA. "... 
Printer Friendly Version
12/07/14Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx for the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery
Seven-fold lower incidence of VTE in patients treated with ISIS-FXI Rx compared with enoxaparin Data published in New England Journal of Medicine and featured at the American Society of Hematology annual meeting Isis to host a webcast at 9:00 a.m. ET on Monday, December 8, 2014 CARLSBAD, Calif., Dec. 7, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today final data from its Phase 2 comparator-controlled study evaluating the incidence of venous thromboembolic e... 
Printer Friendly Version
12/05/14Isis Pharmaceuticals' CEO, Dr. Stanley Crooke, Receives Prestigious SCRIP Lifetime Achievement Award
CARLSBAD, Calif., Dec. 5, 2014 /PRNewswire/ -- Stanley T. Crooke, Ph.D., M.D., founder, CEO and chairman of the board of directors of Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), has been awarded the 2014 SCRIP Lifetime Achievement Award, one of the most prestigious of its kind in the pharmaceutical and biotechnology industries worldwide. Dr. Crooke was selected for the lifetime achievement award by an independent panel of global life sciences experts, based on Dr. Crooke's dedication to advancing... 
Printer Friendly Version
12/03/14ISIS-APOCIII Rx Phase 2 Study in Patients With Familial Chylomicronemia Published in the New England Journal of Medicine
Substantial reductions of up to 86% in triglycerides observed All patients achieved a triglyceride level <500 mg/dL during study First study to support the role of apoC-III as a key regulator of triglyceride metabolism utilizing multiple pathways CARLSBAD, Calif., Dec. 3, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that data from a Phase 2 study of ISIS-APOCIIIRx in patients with familial chylomicronemia syndrome (FCS) were published in The New Engl... 
Printer Friendly Version
11/25/14Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Children With Spinal Muscular Atrophy
-- Isis Earns $27 Million Milestone Payment -- CHERISH Trial to Enroll 120 Children With SMA at Clinical Centers Globally CARLSBAD, Calif., Nov. 25, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the initiation of a pivotal Phase 3 study evaluating ISIS-SMNRx in approximately 120 non-ambulatory children with spinal muscular atrophy (SMA).  SMA is a severe and rare genetic neuromuscular disease characterized by muscle atrophy and weakness.  The Phase 3 study,... 
Printer Friendly Version
11/20/14ISIS-STAT3 Rx and ISIS-AR Rx Data Presented by AstraZeneca at European Cancer Symposium
CARLSBAD, Calif., Nov. 20, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that data from two drugs in its anti-cancer franchise will be presented by researchers at AstraZeneca in three presentations at the 26th European Organization for Research and Treatment of Cancer (EORTC) – the National Cancer Institute (NCI) – and the American Association for Cancer Research (AACR) symposium.  Results from a Phase 1/2 clinical study presented today provided preliminary evide... 
Printer Friendly Version
11/18/14Genzyme and Isis Present KYNAMRO® Clinical Data at the American Heart Association
CAMBRIDGE, Mass. & CARLSBAD, Calif.--(BUSINESS WIRE)--Nov. 18, 2014-- Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc. (NASDAQ: ISIS), today announced that new two-year data from a phase 3 long-term extension study of KYNAMRO® (mipomersen sodium) injection was presented at a scientific session at the annual American Heart Association meeting in Chicago, IL. In the study, a retrospective analysis showed that patients treated with KYNAMRO for a mean of two years had a sign... 
Printer Friendly Version
11/18/14Isis Pharmaceuticals to Host Webcast to Discuss ISIS-FXI Rx Data Presented at the ASH Annual Meeting
- Webcast scheduled on Monday, December 8 at 9:00 a.m. Eastern Time CARLSBAD, Calif., Nov. 18, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will host a live webcast on Monday, December 8, 2014 at 9:00 a.m. Eastern Time to discuss the ISIS-FXIRx data presented at the 56th American Society of Hematology Annual Meeting and Exposition.  Interested parties may listen to the call by dialing 877-443-5662 or access the webcast at www.isispharm.com.  A w... 
Printer Friendly Version
11/17/14Cure SMA Presents Isis Pharmaceuticals with SMA Breakthrough Award
ELK GROVE VILLAGE, Ill., Nov. 17, 2014 /PRNewswire-USNewswire/ -- On November 15, Isis Pharmaceuticals ISIS, -0.53% was presented with the 2014 SMA Breakthrough Award as part of the Cure SMA Gala of Hope in Seal Beach, CA. The award was accepted by Stanley T Crooke, Ph.D., M.D., who is the founder, chairman, and chief executive officer of Isis Pharmaceuticals. The award was presented by Kenneth Hobby, president of Cure SMA, an organization that has grown from grassroots beginnings to become ... 
Printer Friendly Version
11/14/14Isis Pharmaceuticals to Present at Upcoming Investor Conferences
CARLSBAD, Calif., Nov. 14, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at: Stifel 2014 Healthcare Conference on Wednesday, November 19, 2014 at 8:35 a.m. ET in New York, NY; Goldman Sachs US Emerging/SMID Cap Growth Conference on Thursday, November 20, 2014 at 7:30 a.m. ET in New York, NY; 2014 Deutsche Bank BioFEST on Monday, December 1, 2014 at 8:40 a.m. ET in Bost... 
Printer Friendly Version
11/13/14AstraZeneca and Isis Pharmaceuticals to Co-Develop Targeted Oligonucleotide Delivery Methods
CARLSBAD, Calif., Nov. 13, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) and AstraZeneca today announced a strategic alliance to discover and develop novel delivery methods for antisense oligonucleotides. The new delivery approaches seek to target the desired tissue more effectively. The agreement builds on an existing collaboration between AstraZeneca and Isis Pharmaceuticals, a leader in the field of antisense, and supports AstraZeneca's research and development capabilities i... 
Printer Friendly Version
11/12/14Isis Pharmaceuticals Prices Offering of $425 Million of 1.00% Convertible Senior Notes
CARLSBAD, Calif., Nov. 12, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the pricing of its offering of $425.0 million aggregate principal amount of Convertible Senior Notes due 2021 (the "Convertible Notes") in a private placement. Isis also granted the initial purchasers of the Convertible Notes a 30-day option to purchase up to an additional $75.0 million aggregate principal amount of the Convertible Notes, solely to cover over-allotments, if any. The sale of ... 
Printer Friendly Version
11/10/14Isis Pharmaceuticals Announces Proposed Offering of $425 Million of Convertible Senior Notes
CARLSBAD, Calif., Nov. 10, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it intends to offer, subject to market and other considerations, $425.0 million aggregate principal amount of Convertible Senior Notes due 2021 (the "Convertible Notes") in a private placement.  Isis also intends to grant to the initial purchasers of the Convertible Notes a 30-day option to purchase up to an additional $63.75 million aggregate principal amount of the Convertible Notes, ... 
Printer Friendly Version
11/07/14Isis Pharmaceuticals Reports Financial Results and Highlights for Third Quarter 2014
-- Conference Call Webcast Friday, November 7, 11:30 a.m. ET at www.isispharm.com CARLSBAD, Calif., Nov. 7, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today reported a pro forma net operating loss (NOL) of $13.4 million and $34.9 million for the three and nine months ended September 30, 2014, respectively, compared to an NOL of $22.7 million and $23.5 million for the same periods in 2013.  Isis' revenue increased by more than 20% during the first nine months of 2014 compar... 
Printer Friendly Version
11/06/14Isis Pharmaceuticals Earns $10 Million Milestone Payment From Biogen Idec for Advancement of ISIS-BIIB3 Rx
CARLSBAD, Calif., Nov. 6, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $10 million milestone payment from Biogen Idec related to the initiation of investigational new drug (IND)-supporting studies of ISIS-BIIB3Rx.  ISIS-BIIB3Rx is a recently identified development candidate designed to inhibit an undisclosed target to treat a neurodegenerative disease.  "Our collaboration with Biogen Idec has been productive and has allowed us to signi... 
Printer Friendly Version
11/05/14Isis Pharmaceuticals Earns $7.5 Million Milestone Payment From AstraZeneca
AstraZeneca advances ISIS-STAT3 Rx in Clinical Development CARLSBAD, Calif., Nov. 5, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $7.5 million milestone payment, the first of two milestone payments totaling $15 million, from AstraZeneca for the advancement of ISIS-STAT3Rx, also referred to as AZD9150, in patients with advanced cancers.  Isis will earn the second $7.5 million milestone payment from AstraZeneca upon initiation of a Phase 2 ... 
Printer Friendly Version
11/03/14Isis Pharmaceuticals Earns $5 Million in Milestone Payment From GSK for Advancement of ISIS-GSK5 Rx
CARLSBAD, Calif., Nov. 3, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $5 million milestone payment from GSK related to the designation of ISIS-GSK5Rx as a development candidate.  ISIS-GSK5Rx is an antisense drug designed to treat an undisclosed ocular disease. "ISIS-GSK5Rx is the second drug in our collaboration with GSK to enter development to treat an ocular disease.  This drug utilizes the unique properties of antisense to selective... 
Printer Friendly Version
10/31/14Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call
CARLSBAD, Calif., Oct. 31, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast:   What: Isis Pharmaceuticals' Third Quarter 2014 Financial Results and Highlights Conference Call When: Friday, November 7 at 11:30 a.m. ET / 8:30 a.m. PT Where: www.isispharm.com How: Live on the Internet. Simply log onto our websi... 
Printer Friendly Version
10/30/14Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference
CARLSBAD, Calif., Oct. 30, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Nomura Biotechnology Conference on Thursday, November 6, 2014 at 8:30 a.m. ET in Boston, MA. A live webcast of the presentation will be available on the "Investors & Media" section of the Company's website, www.isispharm.com.  A replay will be available on the Isis website within 48 hours a... 
Printer Friendly Version
10/10/14Isis Pharmaceuticals Reports Data From ISIS-SMN Rx Phase 2 Studies in Infants and Children With Spinal Muscular Atrophy
Phase 3 ENDEAR study in infants with SMA enrolling; on track to initiate Phase 3 study in children with SMA later this year Isis to host a webcast at 11:30 a.m. EDT on Friday, October 10 CARLSBAD, Calif., Oct. 10, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today provided an update on its ongoing open-label Phase 2 clinical studies of ISIS-SMNRx in infants and children with spinal muscular atrophy (SMA) at the 19th International World Muscle Society (WMS) Congress in Ber... 
Printer Friendly Version
10/09/14Isis Pharmaceuticals Earns $18 Million From GSK for Advancing ISIS-TTR Rx
CARLSBAD, Calif., Oct. 9, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned an $18 million milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP).  "ISIS-TTRRx is the most advanced drug in our collaboration with GSK, and aside from KYNAMRO, it is also the furthest advanced in our late-stage clinical pipeline.  We have patients who have... 
Printer Friendly Version
10/02/14Isis Pharmaceuticals to Host Webcast to Discuss ISIS-SMN Rx Results Presented at the World Muscle Society Congress
CARLSBAD, Calif., Oct. 2, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What: Webcast and conference call to provide an update on the ongoing open-label Phase 2 clinical studies of ISIS-SMNRx in infants and children with spinal muscular atrophy (SMA), which will be presented on the morning (CEST) of Friday, October 10 at the 19th International World Muscle Society in Berlin, Germany When:    ... 
Printer Friendly Version
10/01/14Isis Pharmaceuticals Earns $1.5 Million From GSK for the Advancement of ISIS-GSK4 Rx
CARLSBAD, Calif., Oct. 1, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1.5 million milestone payment from GSK related to the advancement of the program to develop ISIS-GSK4Rx to treat an undisclosed ocular disease. "Our collaboration with GSK has been very productive resulting in four drugs in development," said B. Lynne Parshall, chief operating officer at Isis.  "We look forward to advancing ISIS-GSK4Rx into clinical development and... 
Printer Friendly Version
09/24/14Isis Pharmaceuticals to Present at the Leerink Partners Rare Disease Roundtable
CARLSBAD, Calif., Sept. 24, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Leerink Partners Rare Disease Roundtable on Wednesday, October 1, 2014 at 8:00 a.m. ET in New York, NY. A live webcast of the presentation will be available on the "Investors & Media" section of the Company's website, www.isispharm.com.  A replay will be available on the Isis website withi... 
Printer Friendly Version
09/17/14Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin
CARLSBAD, Calif., Sept. 17, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced that it has earned a $4 million milestone payment from Achaogen, Inc. (NASDAQ: AKAO) associated with the initiation of a Phase 3 study of plazomicin in patients with serious multi-drug resistant (MDR), gram-negative bacterial infections.  The Phase 3 study is designed as a superiority study to evaluate the efficacy and safety of plazomicin compared to colistin in patients with bloodstream infecti... 
Printer Friendly Version
09/03/14Isis Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference
CARLSBAD, Calif., Sept. 3, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Morgan Stanley Global Healthcare Conference on Monday, September 8, 2014 at 12:50 p.m. ET in New York, NY. A live webcast of the presentation will be available on the "Investors & Media" section of the Company's website, www.isispharm.com.  A replay will be available on the Isis website wit... 
Printer Friendly Version
09/02/14Drugs from Isis' Lipid Franchise Highlighted at European Society of Cardiology Congress 2014
KYNAMRO®, ISIS-APOCIIIRX AND ISIS-APO(A)RX DATA PRESENTED CARLSBAD, Calif., Sept. 2, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that data from three drugs in its lipid franchise were highlighted in four presentations at the 2014 European Society of Cardiology (ESC) Congress in Barcelona Spain. Isis has created a lipid franchise of antisense drugs designed to provide effective and safe therapeutic options to treat patients with lipid disorders.  This franchi... 
Printer Friendly Version
08/28/14Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-APOCIII Rx in Patients with FCS
CARLSBAD, Calif., Aug. 28, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the initiation of a Phase 3 study evaluating ISIS-APOCIIIRx in patients with familial chylomicronemia syndrome (FCS).  FCS is a rare orphan disease, characterized by extremely high triglyceride levels, that affects an estimated 3,000 to 5,000 patients worldwide.  The Phase 3 study of ISIS-APOCIIIRx is a randomized, double-blind, placebo-controlled, six month study in approximately 50 patients diag... 
Printer Friendly Version
08/15/14Isis Pharmaceuticals Earns $2M from the Advancement of ISIS-SMN Rx in Children with Spinal Muscular Atrophy
CARLSBAD, Calif., Aug. 15, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $2 million milestone payment from Biogen Idec related to the advancement of the ongoing open-label extension study of ISIS-SMNRx in children with spinal muscular atrophy (SMA).  The open-label extension study of ISIS-SMNRx is offered to those children with SMA who have completed dosing in Isis' previous studies.  In this study, children with SMA are receiving a 12 ... 
Printer Friendly Version
08/04/14Isis Reports Financial Results and Highlights for Second Quarter 2014
- $40 million in milestone payments from partners drives improved quarterly financial performance - Conference Call Webcast Monday, August 4, 10:30 a.m. ET at www.isispharm.com CARLSBAD, Calif., Aug. 4, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today reported pro forma net operating income of $1.1 million and a pro forma net operating loss (NOL) of $21.5 million for the three and six months ended June 30, 2014, respectively, compared to an NOL of $5.3 million and $799,... 
Printer Friendly Version
08/01/14Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy
-- ENDEAR Trial To Enroll 110 SMA Infants at Sites Globally -- Dosage of First Infant Will Trigger $18 Million Milestone Payment CARLSBAD, Calif., Aug. 1, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the initiation of a pivotal Phase 3 study evaluating ISIS-SMNRx in infants with spinal muscular atrophy (SMA), the most common genetic cause of infant mortality. Isis plans to dose the first infant in this study within the next few weeks, at which ... 
Printer Friendly Version
07/28/14Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call
CARLSBAD, Calif., July 28, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What: Isis Pharmaceuticals' Second Quarter 2014 Financial Results and Highlights Conference Call When: Monday, August 4 at 10:30 a.m. ET / 7:30 a.m. PT Where: www.isispharm.com How: Live on the Internet. Simply l... 
Printer Friendly Version
07/17/14Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-APO(a) Rx in Patients with High Lp(a)
CARLSBAD, Calif., July 17, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc.  (NASDAQ: ISIS) announced the initiation of a Phase 2 study evaluating ISIS-APO(a)Rx in patients with high lipoprotein(a), or Lp(a), an independent risk factor for cardiovascular disease.  Patients with high levels of Lp(a) have an increased risk of atherosclerosis, coronary heart disease, aortic stenosis, heart attack and stroke.  ISIS-APO(a)Rx is designed to reduce Lp(a) by inhibiting the production of apolipoprotein(a)... 
Printer Friendly Version
07/16/14Isis Pharmaceuticals Earns $1 Million from GSK for Advancing ISIS-TTR Rx
CARLSBAD, Calif., July 16, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1 million milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP).  ISIS-TTRRx is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripher... 
Printer Friendly Version
07/02/14Isis Pharmaceuticals Earns $1 Million From GSK for Advancing Hepatitis B Virus Program
CARLSBAD, Calif., July 2, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1 million payment from GlaxoSmithKline (GSK) related to the advancement of its program to develop antisense drugs to treat hepatitis B virus (HBV). "Our collaboration with GSK has been very productive resulting in three novel antisense drugs in our pipeline.  We look forward to continuing to advance these drugs and add additional new drugs to our pipeline with GSK,"... 
Printer Friendly Version
06/24/14Isis Pharmaceuticals Earns $1 Million From GSK for Advancing ISIS-TTR Rx
CARLSBAD, Calif., June 24, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1 million milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP).  ISIS-TTRRx is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripher... 
Printer Friendly Version
06/17/14Isis Pharmaceuticals Earns $10 Million Milestone Payment from Biogen Idec
CARLSBAD, Calif., June 17, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today it has earned a $10 million milestone payment from Biogen Idec associated with the validation of an undisclosed target to treat a neurological disorder.  This is the first milestone payment under Isis' and Biogen Idec's 2013 strategic collaboration to advance the treatment of neurological disorders.  This collaboration combines Biogen Idec's expertise in neurology with Isis' leadership in an... 
Printer Friendly Version
06/16/14Isis Pharmaceuticals Reports Final Phase 2 Data on ISIS-GCGR RX Showing Significant Reduction in HbA1c in Patients with Type 2 Diabetes
Up to 2.25 percentage point reduction in HbA1c achieved after only 13 weeks of dosing Treated patients achieved statistically significant reductions in measures of glucose control Isis to host an investor event and live webcast at 6:30 a.m. PDT on Monday, June 16 in San Francisco CARLSBAD, Calif., June 16, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the final results from its Phase 2 study of ISIS-GCGRRx in patients with type 2 diabetes uncontrolled on... 
Printer Friendly Version
06/12/14Isis Pharmaceuticals to Present at the 2014 Wells Fargo Healthcare Conference
CARLSBAD, Calif., June 12, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 2014 Wells Fargo Healthcare Conference at 1:10 p.m. ET and participate in the Gene Manipulation Panel at 2:20 p.m. ET on Tuesday, June 17, 2014 in Boston, MA. A live webcast of the presentations will be available on the "Investors & Media" section of the Company's website, www.isispharm.com... 
Printer Friendly Version
06/11/14Isis Pharmaceuticals to Host Investor Event to Discuss ISIS-GCGR Rx Phase 2 Data Presented at the 2014 ADA Scientific Sessions
Event and webcast scheduled on Monday, June 16 at 6:30 a.m. Pacific Time CARLSBAD, Calif., June 11, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will host an investor event and a live webcast on Monday, June 16, 2014 at 6:30 a.m. Pacific Time to discuss the ISIS-GCGRRx Phase 2 data presented at the American Diabetes Association's 74th Scientific Sessions in San Francisco, CA.  Interested parties may register to attend the event in San Francisco,... 
Printer Friendly Version
06/10/14Isis Pharmaceuticals Earns $15 Million from AstraZeneca for Initiation of Phase 1 Study of ISIS-AR Rx
Successful collaboration with AstraZeneca includes two novel cancer drugs in clinical development CARLSBAD, Calif., June 10, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that AstraZeneca has initiated a Phase 1 clinical study of ISIS-ARRx in patients with cancer.  Isis earned a $15 million milestone payment associated with the clinical advancement of ISIS-ARRx.  ISIS-ARRx is an antisense drug designed to treat patients with prostate cancer by inhibiting the p... 
Printer Friendly Version
06/09/14Isis Pharmaceuticals Initiates Phase 1 Study of ISIS-DMPK Rx to Treat Myotonic Dystrophy Type 1
Isis Earns $14 Million Milestone Payment from Biogen Idec ISIS-DMPKRx is the Second Generation 2.5 Antisense Drug to Enter the Clinic CARLSBAD, Calif., June 9, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated a Phase 1 study for ISIS-DMPKRx.  Isis earned a $14 million milestone payment from Biogen Idec associated with this achievement.  ISIS-DMPKRx is designed to reduce the production of toxic dystrophia myotonica-protein ... 
Printer Friendly Version
06/04/14Isis Pharmaceuticals to Present at the Goldman Sachs 35th Annual Global Healthcare Conference
CARLSBAD, Calif., June 4, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Goldman Sachs 35th Annual Global Healthcare Conference on Wednesday, June 11, 2014 at 8:40 a.m. PT in Rancho Palos Verdes, CA. A live webcast of the presentation will be available on the "Investors & Media" section of the Company's website, www.isispharm.com.  A replay will be available on the I... 
Printer Friendly Version
06/03/14Isis Pharmaceuticals to Present a General Corporate Update at its 2014 Annual Meeting of Stockholders and Open House
CARLSBAD, Calif., June 3, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a general corporate update in conjunction with its 2014 Annual Meeting of Stockholders and Open House on Tuesday, June 10 at 2:10 p.m. Pacific Time in Carlsbad, CA. The agenda for the meeting is as follows: 2:00 p.m. – 2:10 p.m. Annual Meeting of Stockholders (only for stockholders of record as of April 26, 2014) 2:1... 
Printer Friendly Version
05/22/14Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx in the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery
Seven-fold lower incidence of VTEs in patients treated with ISIS-FXIRx compared to enoxaparin CARLSBAD, Calif., May 22, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today positive top-line data from a Phase 2 comparator-controlled study evaluating the incidence of venous thrombolic events (VTE) in patients treated with ISIS-FXIRx undergoing total knee replacement surgery, or total knee arthroplasty (TKA).  ISIS-FXIRx inhibits the production of Factor XI, a coagulat... 
Printer Friendly Version
05/20/14Isis Pharmaceuticals Initiates Phase 1 Study of ISIS-PKK Rx
CARLSBAD, Calif., May 20, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it initiated a Phase 1 clinical study of ISIS-PKKRx.  ISIS-PKKRx is an antisense drug in development to treat patients with hereditary angioedemia (HAE).  HAE is a rare genetic disease that is characterized by rapid and painful attacks of inflammation in the hands, feet, limbs, face, abdomen, larynx and trachea.  HAE affects approximately 20,000 patients in the United States and Europe a... 
Printer Friendly Version
05/16/14Webcast Alert: Isis Pharmaceuticals Announces its R&D Day Presentation
CARLSBAD, Calif., May 16, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What: Isis Pharmaceuticals' R&D Day Presentation When: Thursday, May 22 at 12:00 p.m. ET / 9:00 a.m. PT Where: www.isispharm.com How: Live on the Internet.  Simply log onto our website listed above. ... 
Printer Friendly Version
05/15/14Isis Pharmaceuticals Earns $3.0 Million from GSK
CARLSBAD, Calif., May 15, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $3.0 million milestone payment from GlaxoSmithKline (GSK) related to the initiation of a natural history study, which will support the advancement of one of the alliance programs.  "We have had a very productive alliance with GlaxoSmithKline, from which we have advanced three antisense drugs in our pipeline, including ISIS-TTRRx, which is currently in Phase 3 develo... 
Printer Friendly Version
05/14/14Isis Pharmaceuticals Reports Phase 2 Data on ISIS-GCGR Rx Showing Significant Reduction in HbA1c in Patients With Type 2 Diabetes
Greater than 2 percentage point reduction in HbA1c achieved after only 13 weeks of dosing CARLSBAD, Calif., May 14, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today positive data from a Phase 2 study of ISIS-GCGRRx in patients with type 2 diabetes uncontrolled on stable metformin therapy.  In this study, patients in the per protocol efficacy population treated with ISIS-GCGRRx achieved statistically significant reductions in measures of glucose control.  The abso... 
Printer Friendly Version
05/13/14Isis Pharmaceuticals to Present at the UBS Global Healthcare Conference
CARLSBAD, Calif., May 13, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the UBS Global Healthcare Conference on Wednesday, May 21, 2014 at 8:00 a.m. ET in New York, NY. A live webcast of the presentation will be available on the "Investors & Media" section of the Company's website, www.isispharm.com.  A replay will be available on the Isis website within 48 hours an... 
Printer Friendly Version
05/08/14Genzyme and Isis Receive Corporate Award from the National Organization for Rare Disorders (NORD) for the Development of KYNAMRO®
CAMBRIDGE, Mass. & CARLSBAD, Calif.--(BUSINESS WIRE)-- Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), and Isis Pharmaceuticals Inc. (ISIS), today announced that they have received the 2014 Partners in Progress Corporate Award from NORD in recognition of KYNAMRO® (mipomersen sodium) injection. KYNAMRO, selected for being a very important orphan therapy to reach the market in the United States, is an adjunct to lipid-lowering medications and diet to reduce l... 
Printer Friendly Version
05/08/14Isis Pharmaceuticals to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
CARLSBAD, Calif., May 8, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Bank of America Merrill Lynch 2014 Health Care Conference on Thursday, May 15, 2014 at 11:20 a.m. PT in Las Vegas, NV. A live webcast of the presentation will be available on the "Investors & Media" section of the Company's website, www.isispharm.com.  A replay will be available on the Isis w... 
Printer Friendly Version
05/06/14Isis Reports Financial Results and Highlights for First Quarter 2014
-Conference Call Webcast Tuesday, May 6, 11:30 a.m. ET at www.isispharm.com CARLSBAD, Calif., May 6, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today reported a pro forma net operating loss (NOL) of $22.6 million for the three months ended March 31, 2014 compared to pro forma operating income of $4.5 million for the same period in 2013.  Isis' first quarter 2014 pro forma NOL was higher than the same period last year primarily due to variations in the timing of milestone p... 
Printer Friendly Version
05/02/14Isis Reports Final Phase 2 Data on ISIS-APOCIII Rx in Patients With Familial Chylomicronemia
Significant reductions of more than 1,500 mg/dL in triglycerides observed Significant reductions in chylomicrons observed CARLSBAD, Calif., May 2, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the final data from its Phase 2 study of ISIS-APOCIIIRx as a monotherapy in patients with familial chylomicronemia syndrome, or FCS.  In this open-label study, three patients with FCS treated with ISIS-APOCIIIRx achieved substantial reductions in triglycerides with all thre... 
Printer Friendly Version
05/01/14Isis Pharmaceuticals to Present at the Deutsche Bank 39th Annual Health Care Conference
CARLSBAD, Calif., May 1, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Deutsche Bank 39th Annual Health Care Conference on Wednesday, May 7, 2014 at 12:50 p.m. ET in Boston, MA. A live webcast of the presentation will be available on the "Investors & Media" section of the Company's website, www.isispharm.com.  A replay will be available on the Isis website withi... 
Printer Friendly Version
05/01/14Isis Reports Final Phase 2 Data on ISIS-APOCIII Rx in Patients With High Triglycerides and Type 2 Diabetes
- 69 percent reduction in triglycerides achieved - 1.22 percent reduction in HbA1c achieved CARLSBAD, Calif., May 1, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the final results from its Phase 2 study of ISIS-APOCIIIRx in patients with high triglycerides and type 2 diabetes.  In this study, patients treated with ISIS-APOCIIIRx achieved statistically significant average mean percent reduction from baseline of 88 percent (p=0.02) in apolipoprotein C-III (apoC-II... 
Printer Friendly Version
04/30/14ISIS Pharmaceuticals' and Biogen idec's innovative collaboration voted breakthrough alliance of 2014
CARLSBAD, Calif., April 30, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that the strategic alliance between Isis and Biogen Idec (NASDAQ:BIIB) has been honored with the Alliance 2014 Breakthrough Award.  The award, sponsored by Thomson Reuters Recap, was presented at the Allicense 2014 Conference in San Francisco on April 29, 2014.     "We are grateful for the award and recognition of our innovative and productive partnership with Isis," said Richard Brud... 
Printer Friendly Version
04/30/14Webcast Alert: Isis Pharmaceuticals' First Quarter 2014 Financial Results Conference Call
CARLSBAD, Calif., April 30, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What:      Isis Pharmaceuticals' First Quarter 2014 Financial Results and Highlights Conference Call When:       Tuesday, May 6 at 11:30 a.m. ET / 8:30 a.m. PT Where:     www.isispharm.com How:        Live on the Internet.  Simply log onto ... 
Printer Friendly Version
04/29/14Isis Reports Updated Results from ISIS-SMN Rx Clinical Studies in Infants and Children with Spinal Muscular Atrophy
Results presented at the American Academy of Neurology meeting On track to initiate Phase 3 study in infants with SMA mid-year On track to initiate Phase 3 study in children with SMA in the second half of the year Isis to host an investor event and live webcast at 6:00 p.m. EDT on Tuesday, April 29 in Philadelphia CARLSBAD, Calif., April 29, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today provided an update on both of its ongoing open-label Phas... 
Printer Friendly Version
04/22/14Isis Pharmaceuticals to Host Investor Event to Discuss ISIS-SMN Rx Data Presented at the 2014 AAN Annual Meeting
- Event and webcast scheduled on Tuesday, April 29 at 6:00 p.m. Eastern Time CARLSBAD, Calif., April 22, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will host an investor event and a live webcast on Tuesday, April 29, 2014 at 6:00 p.m. Eastern Time to discuss the ISIS-SMNRx data presented at the 2014 American Academy of Neurology Annual Meeting.  Interested parties may register to attend the event in Philadelphia, PA, or access the webcast on t... 
Printer Friendly Version
04/01/14Isis Pharmaceuticals to Present at the 13th Annual Needham Healthcare Conference
CARLSBAD, Calif., April 1, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 13th Annual Needham Healthcare Conference on Tuesday, April 8 , 2014 at 12:50 p.m. ET in New York, NY. A live webcast of the presentation will be available on the "Investors & Media" section of the Company's website, www.isispharm.com.  A replay will be available on the Isis website within ... 
Printer Friendly Version
03/31/14Isis Reports Final Phase 2 Data On ISIS-APOCIII Rx In Patients With High Triglycerides Taking Fibrates
- Reductions of up to 64 percent in triglycerides achieved - Reductions in atherogenic particles and increases in HDL particles observed - Data presented today at the American College of Cardiology CARLSBAD, Calif., March 31, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the final results from its Phase 2 study of ISIS-APOCIIIRx in patients with high to severely high triglycerides on stable doses of fibrates.  In this study, patients treated with ISIS-APOCIIIR... 
Printer Friendly Version
03/24/14Isis Announces Antisense Targeting Of HBV Produces Dose-Dependent Reductions In Hepatitis B Virus In An Animal Model Of HBV
Data to be presented in April at the European Association for the Study of the Liver Meeting Isis' antisense drug targeting HBV, ISIS-HBVRx, in an ongoing Phase 1 study planned to complete this year CARLSBAD, Calif., March 24, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced that treatment with an antisense compound targeting hepatitis B virus (HBV) produced dose-dependent reductions in all measured liver and serum viral markers of HBV infection in animal models of ... 
Printer Friendly Version
03/19/14Isis Pharmaceuticals Initiates Phase 1 Study of ISIS-ANGPTL3 Rx to Treat Hyperlipidemia
CARLSBAD, Calif., March 19, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated a Phase 1 clinical study for ISIS-ANGPTL3Rx, an antisense drug targeting angiopoietin-like 3 protein (ANGPTL3), an independent risk factor for cardiovascular disease. ISIS-ANGPTL3Rx is designed to act as a broad dyslipidemia agent.  By reducing ANGPTL3, ISIS-ANGPTL3Rx has the potential to reduce LDL-cholesterol and triglycerides, and to increase insulin sensitivity.  I... 
Printer Friendly Version
03/06/14Isis Pharmaceuticals to Present at the Barclays Global Healthcare Conference
CARLSBAD, Calif., March 6, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Barclays Global Healthcare Conference on Thursday, March 13, 2014 at 9:00 a.m. ET in Miami, FL. A live webcast of the presentation will be available on the "Investors & Media" section of the Company's website, www.isispharm.com.  A replay will be available on the Isis website within 48 hour... 
Printer Friendly Version
03/03/14ISIS Pharmaceuticals Earns $1 Million from GSK for Advancing ISIS-TTR Rx
CARLSBAD, Calif., March 3, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1 million milestone payment from GlaxoSmithKline (GSK) related to the initiation of an open-label extension study of ISIS-TTRRx, which is being offered to those patients with familial amyloid polyneuropathy (FAP) who have completed dosing in the Phase 2/3 study of ISIS-TTRRx.  ISIS-TTRRx is an antisense drug in development with GSK for the treatment of transthyr... 
Printer Friendly Version
02/28/14Isis Reports Financial Results And Highlights For 2013
- Outperforms 2013 Projections for Pro Forma Net Operating Loss and Year-end Cash - Conference Call Webcast Friday, February 28, 11:30 a.m. ET at www.isispharm.com CARLSBAD, Calif., Feb. 28, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its 2013 financial results and reviewed the highlights of the year.  Isis ended the year in a strong financial position and outperformed both its pro forma net operating loss (NOL) guidance and its cash guidance for the year... 
Printer Friendly Version
02/25/14Isis Pharmaceuticals to Present at the Cowen 34th Annual Health Care Conference
CARLSBAD, Calif., Feb. 25, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Cowen and Company 34th Annual Health Care Conference on Tuesday, March 4, 2014 at 8:40 a.m. ET in Boston, MA. A live webcast of the presentation will be available on the "Investors & Media" section of the Company's website, www.isispharm.com.  A replay will be available on the Isis website ... 
Printer Friendly Version
02/21/14Isis Pharmaceuticals Reports Interim Results from ISIS-SMN Rx Phase 2 Study in Infants with Spinal Muscular Atrophy
On track to initiate Phase 3 study in infants with SMA in the middle of this year Conference Call Scheduled for Monday, February 24, 2014 at 8:30 am Eastern Time CARLSBAD, Calif., Feb. 21, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today provided an update on its ongoing open label, multiple dose Phase 2 study of ISIS-SMNRx in infants with spinal muscular atrophy (SMA).  To date, all four infants in the 6 mg cohort have been in the study for over six months and are now ... 
Printer Friendly Version
02/21/14Isis Pharmaceuticals Reports Interim Results from ISIS-SMN Rx Multiple Dose Study in Children with Spinal Muscular Atrophy
Average increase of 3.7 points observed in muscle function score in SMA children treated with 9 mg of ISIS-SMN Rx ISIS-SMN Rx increases SMN protein in children with SMA On track to initiate Phase 3 study in children with SMA later this year Conference Call Scheduled for February 24, 2014 at 8:30 am Eastern Time CARLSBAD, Calif., Feb. 21, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced top-line results from an ongoing open-label, multiple-dose study of I... 
Printer Friendly Version
02/20/14Webcast Alert: Isis Pharmaceuticals' 2013 Financial Results and Highlights Conference Call
CARLSBAD, Calif., Feb. 20, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What: Isis Pharmaceuticals' 2013 Financial Results and Highlights Conference Call When: Friday, February 28 at 11:30 a.m. ET / 8:30 a.m. PT Where: www.isispharm.com How: Live on the Internet.  Simply log onto our website listed above. ... 
Printer Friendly Version
02/19/14Isis Pharmaceuticals to Present at the 2014 RBC Capital Markets Global Healthcare Conference
CARLSBAD, Calif., Feb. 19, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 2014 RBC Capital Markets Global Healthcare Conference on Wednesday, February 26, 2014 at 2:05 p.m. ET in New York, NY. (Logo: http://photos.prnewswire.com/prnh/20130807/LA60006LOGO) A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company... 
Printer Friendly Version
02/14/14Isis Announces Positive Opinion on European Orphan Drug Designation for ISIS-TTR Rx
CARLSBAD, Calif., Feb. 14, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that the Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending ISIS-TTRRx for designation as an orphan medicinal product for the treatment of ATTR-Amyloidosis to the European Commission (EC). The opinion will be subject to review by the EC, which ultimately grants the decision on orphan drug designation.  ATTR-Amyloidosis, or TTR amyloidosis, is a severe ... 
Printer Friendly Version
02/13/14Isis Pharmaceuticals Advances ISIS-SMN Rx in Infants and Children with Spinal Muscular Atrophy
--Isis will receive $9.3 million in milestone payments -- CARLSBAD, Calif., Feb. 13, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that the first child in the 12 mg group was dosed in the ongoing Phase 2 study evaluating ISIS-SMNRx in children with spinal muscular atrophy (SMA).  Isis also announced today that the first child was dosed in an open–label extension study, which is being offered to those children with SMA who have completed dosing in Isis' previou... 
Printer Friendly Version
02/06/14Isis Pharmaceuticals to Present at the Leerink Global Healthcare Conference
CARLSBAD, Calif., Feb. 6, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 2014 Leerink Global Healthcare Conference on Thursday, February 13, 2014 at 1:50 p.m. ET in New York, NY. (Logo: http://photos.prnewswire.com/prnh/20130807/LA60006LOGO) A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's website, ww... 
Printer Friendly Version
02/03/14Joseph Loscalzo, M.D., Ph.D., Joins Isis Pharmaceuticals' Board of Directors
CARLSBAD, Calif., Feb. 3, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that Joseph Loscalzo, M.D., Ph.D., has joined the company's Board of Directors.  Dr. Loscalzo is head of the department of medicine and physician-in-chief at Brigham & Women's Hospital, Harvard Medical School.  Dr. Loscalzo is recognized as a leading cardiologist focused on identifying the role of endothelial cells and platelets in atherosclerosis and thrombosis. (Logo: http://photos.p... 
Printer Friendly Version
01/13/14Isis Pharmaceuticals to Receive $7.5 Million From Alnylam
CARLSBAD, Calif., Jan. 13, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will receive $7.5 million from Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) from the recently announced alliance between Genzyme and Alnylam.  In addition, Isis has the potential to receive royalties on products and a portion of future milestone payments.  This transaction underscores the value of Isis' innovation and the leadership role Isis has played in the field of nucleic acid b... 
Printer Friendly Version
01/13/14Isis Announces Positive Decision on European Orphan Drug Designation for ISIS-APOCIII Rx
CARLSBAD, Calif., Jan. 13, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that the Committee for Orphan Medicinal Products (COMP) has issued a positive opinion for Orphan Drug Designation for ISIS-APOCIIIRx for the treatment of patients with familial chylomicronemia syndrome (FCS).  FCS is a rare orphan disease characterized by extremely high triglyceride levels that affects an estimated 3,000 to 5,000 patients worldwide. ISIS-APOCIIIRx is a wholly owned drug that... 
Printer Friendly Version
01/06/14Isis Pharmaceuticals to Present at the 32nd Annual J.P. Morgan Healthcare Conference
CARLSBAD, Calif., Jan. 6, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 32nd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2014 at 4:30 p.m. PT in San Francisco, CA. (Logo: http://photos.prnewswire.com/prnh/20130807/LA60006LOGO) A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's websi... 
Printer Friendly Version

Online Investor Kit

Quickly download files right from our Investor Relations Web site.

Learn More

Financial Tearsheet

Download a brief overview of Isis.

Learn More

News Feeds

Get the latest.

Subscribe

Receive Isis alerts in your email.

Sign Up